linjc16/ctgov huggingface dataset:
Release of Cytokines by Stimulated Peripheral Blood Mononuclear Cells (PBMC) From Chronic Periodontitis Subjects

Study Overview
=================
Brief Summary
-----------------
Background and Objective: It has been reported that peripheral blood mononuclear cells (PBMC) from periodontal patients have a different profile of cytokine release when compared to the ones of healthy patients. Cigarette smoking is a recognized risk factor for periodontitis and is known to affect the systemic and local immune responses. Thus, the aim of the present study was to obtain preliminary data about the interaction of periodontal condition and smoking in the secretion of some cytokines by PBMC. Material and Methods: PBMC samples were isolated from 19 donors, divided into generalized chronic periodontitis (P; n=10) and periodontal health (H; n=9) groups. In addition, the smokers and non-smokers of each group were separately evaluated: SP- smokers with severe generalized chronic periodontitis (n=5); SH- periodontally healthy smokers (n=5); NSP- non-smokers with severe generalized chronic periodontitis (n=5) and NSH- periodontally healthy non-smokers (n=4). Cells were incubated for 24-48 hours in 500 µL wells containing RPMI 1640 and stimulated with 1.0 ng/mL of E. coli LPS. Supernatants were used to quantify the amounts of TNF-α, IL-6, IL-8 and IL-10 released using ELISA kits.

Conditions
-----------------
Periodontitis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: periodontitis Exclusion Criteria: diabetes

Ages Eligible for Study
-----------------
Minimum Age: 25 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| PBMC<br> | |
| periodontitis<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
periodontitis, find cytokines in blood of periodontal patients
Long-term Follow-up of Subfoveal Neovascular AMD

Study Overview
=================
Brief Summary
-----------------
Treatment naive patients with subfoveal nAMD initially treated monthly with intravitreal anti-VEGF and subsequently PRN, will be included in this study. Patients will be investigated for the first 2 years monthly and subsequently according to disease activity but at least every two months. Patients will be examined with 4m BCVA ETDRS distance visual acuity, reading acuity measured by Radner-Reading-Charts, contrast sensitivity by Pelli-Robson score, microperimetry and HD-OCT.

Conditions
-----------------
Exudative Age-related Macular Degeneration

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: treatment naive subfoveal AMD, written informed consent, able to read Exclusion Criteria: choroidal neovascularisation due to other ocular diseases, mature cataract

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Long-term visual function performance |  | four years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| change of morphological alterations assessed by SD-OCT |  | four years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
neovascular AMD, Optical coherence tomography, reading acuity, contrast sensitivity
Use of Dexamethasone in Uterine Artery Embolization

Study Overview
=================
Brief Summary
-----------------
The primary purpose of this study is to investigate the effects of dexamethasone on inflammatory reactions after uterine artery embolization. The secondary purpose of this study it to investigate the effects of dexamethasone on postembolization syndrome (severe pain, nasea and vomiting).

Official Title
-----------------
The Effect of Dexamethasone on Inflammatory Response After Uterine Artery Embolization

Conditions
-----------------
Uterine Myoma, Adenomyosis

Intervention / Treatment
-----------------
* Drug: Dexamethasone
* Drug: Normal saline


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Uterine artery embolization due to multiple myoma or adenomyosis Exclusion Criteria: Diabetic mellitus Steroid administration Liver or kidney dysfuntion High baseline CRP or leukocytosis (>11,000/μL ) Drug allergy

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Dexamethasone group<br> | Drug: Dexamethasone<br>* Administration of dexamethasone 10 mg IV 1 h before UAE<br>|
| Placebo Comparator: Control group<br> | Drug: Normal saline<br>* Administration of normal saline 2 mL IV 1 h before UAE<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Inflammatory reactions | CRP, WBC, neutrophil (%), cortisol : pre-UAE, post-UAE 12 h, post-UAE-24 h IL-6 : pre-UAE, post-UAE-24 h | 24 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pain | Immediately after UAE, post-UAE 1, 2, 4, 6, 8, 12, 24 h | 24 hours | 
| Nausea and vomiting | Immediately after UAE, post-UAE 1, 2, 4, 6, 8, 12, 24 h | 24 hours | 
| Sucessful rate at 3 month after UAE | Utrerine volume and complete necrosis incidence | 3 month |
Early Versus Delayed Pushing in the Second Stage of Labor

Study Overview
=================
Brief Summary
-----------------
Nulliparous women in spontaneous or induced labour with term singleton pregnancy are randomized into two groups first group (early pushing) in this group patients were allowed to push within one hour after full cervical dilatation whether the vertex was visible or not. Second group (delayed pushing) patients here were asked not to push for maximum of 3 hours or start pushing when the vertex was visible.

Detailed Description
-----------------
Nulliparous women in spontaneous or induced labour with term singleton pregnancy are randomized into two groups first group (early pushing) in this group patients were allowed to push within one hour after full cervical dilatation whether the vertex was visible or not. Second group (delayed pushing) patients here were asked not to push for maximum of 3 hours or start pushing when the vertex was visible. Oxytocin was allowed in both group and fetus was monitored with CTG.

Official Title
-----------------
Early Versus Delayed Pushing in the Second Stage of Labor

Conditions
-----------------
Vaginal Delivery

Intervention / Treatment
-----------------
* Procedure: vaginal delivery


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Healthy women Gestational age 36 to 40 weeks singleton pregnancy Exclusion Criteria: women indicated for cesarean section Medical complications of pregnancy as hypertensive disorders or Diabetes Mellitus Fetal distress Epidural anaesthesia

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 39 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Prevention
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Early pushing during vaginal delivery<br>patients are allowed to push within one hour after full cervical dilatation whether the vertex was visible or not | Procedure: vaginal delivery<br>* vaginal delivery is carried by an expert obstetrician and the need for forceps or ventose is recorded<br>|
| Active Comparator: Delayed pushingduring vaginal delivery<br>patients here are asked not to push for maximum of 3 hours or start pushing when the vertex was visible | Procedure: vaginal delivery<br>* vaginal delivery is carried by an expert obstetrician and the need for forceps or ventose is recorded<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| successful vaginal delivery | success of vaginal delivery | within 3 hours from full cervical dilatation |
Determination of Risk Factors of Ventricular Arrhythmias (VAs) After Implantation of Continuous Flow Left Ventricular Assist Device With Continuous Flow Left Ventricular Assist Device (CF-LVAD)

Study Overview
=================
Brief Summary
-----------------
Determination of risk factors of ventricular arrhythmias (VAs) after implantation of continuous flow left ventricular assist device in order to characterize which patient requires ICD implantation in primary prevention.

Official Title
-----------------
Interest of Implantable Cardioverter-defibrillator in Primary Prevention in Patient With Continuous Flow Left Ventricular Assist Device (CF-LVAD)

Conditions
-----------------
Severe Cardiac Insufficiency

Intervention / Treatment
-----------------
* Other: Implantable cardioverter-defibrillator


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patient above 18 years old Patients with CF-LVAD with or without ICD Exclusion Criteria: Patients subject to major legal protection (safeguarding justice, guardianship, trusteeship), persons deprived of liberty

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Implantable cardioverter-defibrillator|Collection of clinical, biological, hemodynamic and rhythmic data|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Occurrence of early VAs (<30 days post operatively) and late VAs (>30 days post operatively) in patient with CF-LVAD with or without ICD | Clinical, biological, hemodynamic and rhythmic data | 30 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mortality in patients with CF-LVAD with or without VAs |  | 30 days | 
| Mortality in patients with CF-LVAD with or without ICD |  | 30 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Left ventricular assist device, Ventricular Arrhythmias, Implantable Cardioverter-defibrillator
Combination Treatment for Moderate to Severe Acne

Study Overview
=================
Brief Summary
-----------------
To determine if a combination of three currently approved acne products are safe and effective for the treatment of moderate to severe acne

Detailed Description
-----------------
A Phase IV, Open-Label Study Evaluating the treatment for Combination Acne Therapy.

Official Title
-----------------
A Phase IV, Open-Label Study Evaluating the Use of Solodyn (Minocycline HCL Extended-Release Tablets), Ziana, and Triaz Foaming Cloths as Combination Acne Therapy Prior to Treatment With Isotretinoin

Conditions
-----------------
Acne

Intervention / Treatment
-----------------
* Drug: Minocycline, Clindamycin, Tretinoin, Benzoyl Peroxide


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: moderate to severe acne, IGA = 3 or 4 (Investigator Global Assessment) Exclusion Criteria: pregnancy and allergies

Ages Eligible for Study
-----------------
Minimum Age: 12 Years
Maximum Age: 30 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Open Label Combination<br>Solodyn, Ziana, Triaz FC | Drug: Minocycline, Clindamycin, Tretinoin, Benzoyl Peroxide<br>* Solodyn 1 tablet, Q day Ziana Gel, topical Q am Triaz FC, topical Q night<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Proportion of patients showing improvement from Baseline and Week 12 |  | Week 12 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Acne
Noninvasive Evaluation of Hepatic Fibrosis in Chronic Hepatitis C

Study Overview
=================
Brief Summary
-----------------
Chronic viral hepatitis C is a frequent liver disease. It is associated with variable degree of hepatic fibrosis. To date, liver histology is still regarded as the gold standard to detect, diagnose and quantify liver fibrosis. This requires to perform a liver biopsy. Severe complications are associated to this procedure in 0.01 to 0.1% of cases. Because of this, the repetition of the biopsy to evaluate the progression of the disease or the response to treatment poses ethical questions. Also, liver biopsy only explore a minimal portion of the liver and liver fibrosis, which is not homogeneous, may be under- or over-estimated. To avoid risks linked to invasive technique and sampling errors associated to liver biopsy, efforts are being made to develop non-invasive technology to detect and quantitate liver fibrosis. In this study we will perform in patients with chronic hepatitis C, serum tests, fibroscan (elastography of liver parenchyma determined by ultra-sounds), and elastography of liver parenchyma by MRI. This study will allow to determine whether non-invasive tests effectively measure liver fibrosis to compare each non-invase test with results of liver biopsy to determine whether a non-invasive test or a combination of non invasive tests may be used to accurately evaluate liver fibrosis in patients with chronic hepatitis C.

Conditions
-----------------
Hepatitis C, Chronic

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: alteration of liver function tests (ALT, AST) HCV RNA positive Exclusion Criteria: clotting disorder ongoing treatment with anti-coagulant or anti-aggregant advanced or decompensated cirrhosis (Child-Pugh class C) hepatocellular carcinoma other cancer history of surgery for brain aneurysm pace maker or defibrillator ocular metal foreign body

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Chronic viral hepatitis C, HCV RNA, Fibroscan, Fibrotest, hepatic elastography by MRI
Lactate Kinetics in Septic Shock

Study Overview
=================
Brief Summary
-----------------
Lactate kinetics will be studied in hospitalized septic patients using a bolus injection of stable isotopically labeled lactate.

Detailed Description
-----------------
Adult septic patients admitted to the Intensive Care Unit (ICU) or Intermediary Medical Unit in Karolinska University Hospital will be recruited within 72 hours from start of symptoms. Other than fulfilling the definition for sepsis-3, patients need to be equipped with an arterial catheter to be eligible for inclusion. After informed consent (from next of kin when applicable) baseline blood samples are drawn from existing catheter and the subject is given a bolus dose of 20umol/kg 13C-labeled lactate in 20 ml isotonic saline. After this a total of 14 blood samples á 2 ml is drawn in the following 120 minutes. All blood samples are centrifuged and stored in -800 C until analysis. After all subjects have been included sampled are thawed and analyzed for content of endogenous and labeled lactate. Through analysis between their relationship the lactate production and consumption can be quantified.

Official Title
-----------------
Lactate Kinetics in Patients Treated for Septic Shock

Conditions
-----------------
Sepsis, Septic Shock

Intervention / Treatment
-----------------
* Other: Isotopically labeled lactate


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Sepsis Age >17 years Arterial catheter Lactate > 2 mmol at any time point prior to inclusion Exclusion Criteria: Mitochondrial defect Degenerative muscle disease Terminal liver failure

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: All patients<br>All patients receive the same intervention/sampling protocol | Other: Isotopically labeled lactate<br>* A bolus dose of isotopically labeled lactate is given and blood samples from existing catheters are drawn<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Whole body rate of appearance of lactate | The total amount of lactate produced per unit of time | 2 hours | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clearance of lactate | Amount of plasma that is cleared from lactate per unit of time | 2 hours |
Disparity Driven Vergence in Mild Traumatic Brain Injury (mTBI)

Study Overview
=================
Brief Summary
-----------------
This study aims to determine the validity and safety of disparity driven vergence using a portable goggle system (I-PAS) using a pseudorandom ternary sequence of frequencies for testing.

Official Title
-----------------
Examining Disparity Driven Vergence as a Potential Diagnostic Test for Mild Traumatic Brain Injury (mTBI)

Conditions
-----------------
Mild Traumatic Brain Injury

Intervention / Treatment
-----------------
* Device: I-PAS Goggles


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 18 to 65 Both females and males Exclusion Criteria: Central processing disorder Impaired vision without corrective lenses (max 20/60 uncorrected) Moderate to severe hearing loss (>55 decibels (dB) pure tone audiometry (PTA), <50% word identification) Vestibular disorder except for patients recruited for subjects recruited with a history of mild traumatic brain injury to compare to normal participants History of ear surgery other than myringotomy with or without tube placement Pregnant women Prisoners Adults unable to consent

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Injured Participants<br>Participants with mild traumatic brain injury (mTBI) tested using the I-PAS goggles | Device: I-PAS Goggles<br>* Portable, head-mounted display goggle system with integrated eye capture technology<br>|
| Active Comparator: Uninjured Participants<br>Participants with no mild traumatic brain injury (mTBI) tested using the I-PAS goggles | Device: I-PAS Goggles<br>* Portable, head-mounted display goggle system with integrated eye capture technology<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pseudorandom Ternary Sequence of Frequency | Pseudorandom Ternary Sequence of Frequency (reported in Hertz) will be measured via mergence testing using the IPAS goggles. | 15 minutes | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
brain injury, mTBI, TBI, concussion
Randomized Trial of Home Versus Clinic-Based STD Testing

Study Overview
=================
Brief Summary
-----------------
This study randomizes St. Louis men to home-based STD screening or clinic-based STD screening. Home-based screening will be completed through the mail and clinic-based screening in a local clinical setting. We hypothesize that men randomized to home-based screening will be more likely to complete screening.

Official Title
-----------------
A Randomized Trial of Home Versus Clinic-Based STD Testing Among Men

Conditions
-----------------
Chlamydia, Gonorrhea

Intervention / Treatment
-----------------
* Behavioral: Home Screening
* Behavioral: Clinic Screening


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Men Ages 18-45 Residing in St. Louis City or County English-speaking Exclusion Criteria: -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Screening
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Clinic-Based Testing<br>Clinic-based STD screening using self-obtained urine samples in a local university clinical setting. | Behavioral: Clinic Screening<br>* Clinic-based STD screening using self-obtained urine samples in a local university clinical setting.<br>|
| Experimental: Home-Based Testing<br>Home-based STD screening using self-obtained urine samples and study paid postal return of samples. | Behavioral: Home Screening<br>* Home-based STD screening using self-obtained urine samples and study paid postal return of samples.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of men who complete testing in each study arm |  | 12 weeks after enrollment |